CO6361938A2 - Metodo para tratar o prevenir la trombosis usando etexilato de dabigatran o una sal del mismo con un perfil de seguridad mejorado sobre la terapia con warfarina convencional - Google Patents
Metodo para tratar o prevenir la trombosis usando etexilato de dabigatran o una sal del mismo con un perfil de seguridad mejorado sobre la terapia con warfarina convencionalInfo
- Publication number
- CO6361938A2 CO6361938A2 CO11058047A CO11058047A CO6361938A2 CO 6361938 A2 CO6361938 A2 CO 6361938A2 CO 11058047 A CO11058047 A CO 11058047A CO 11058047 A CO11058047 A CO 11058047A CO 6361938 A2 CO6361938 A2 CO 6361938A2
- Authority
- CO
- Colombia
- Prior art keywords
- warfarine
- therapy
- treat
- improved safety
- safety profile
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Un método para prevenir el ictus en un paciente que padece fibrilación auricular, en el que el paciente tiene al menos un factor de riesgo para acontecimientos hemorrágicos mayores, comprendiendo el método administrar al paciente 110 mg b.i.d. de etexilato de dabigatrán, opcionalmente en forma de una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11340408P | 2008-11-11 | 2008-11-11 | |
US23755209P | 2009-08-27 | 2009-08-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6361938A2 true CO6361938A2 (es) | 2012-01-20 |
Family
ID=41463076
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO11058047A CO6361938A2 (es) | 2008-11-11 | 2011-05-11 | Metodo para tratar o prevenir la trombosis usando etexilato de dabigatran o una sal del mismo con un perfil de seguridad mejorado sobre la terapia con warfarina convencional |
Country Status (21)
Country | Link |
---|---|
US (3) | US8962574B2 (es) |
EP (1) | EP2358368A1 (es) |
JP (1) | JP2013510072A (es) |
KR (1) | KR20110086700A (es) |
CN (2) | CN103356614A (es) |
AR (1) | AR074313A1 (es) |
AU (1) | AU2009315729A1 (es) |
BR (1) | BRPI0921479A2 (es) |
CA (1) | CA2738883A1 (es) |
CL (1) | CL2011000798A1 (es) |
CO (1) | CO6361938A2 (es) |
EA (1) | EA201100756A1 (es) |
EC (1) | ECSP11011030A (es) |
IL (1) | IL211852A0 (es) |
MA (1) | MA32786B1 (es) |
MX (1) | MX2011004614A (es) |
NZ (1) | NZ592616A (es) |
PE (1) | PE20110431A1 (es) |
TN (1) | TN2011000228A1 (es) |
TW (1) | TW201022237A (es) |
WO (1) | WO2010055021A1 (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013510072A (ja) | 2008-11-11 | 2013-03-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 従来のワルファリン治療に対して安全性プロフィールが改善されたダビガトランエテキシレートまたはその塩を使用して血栓症を治療または予防するための方法 |
WO2012122024A2 (en) * | 2011-03-04 | 2012-09-13 | Russell Medford | Screening method for identifying patients at risk of drug induced liver injury |
EA201400737A1 (ru) * | 2011-12-22 | 2014-12-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Система доставки на основе множества пеллет с немедленным высвобождением активного вещества |
WO2014001220A1 (en) | 2012-06-25 | 2014-01-03 | Boehringer Ingelheim International Gmbh | Method for prevention of stroke |
WO2014060545A1 (en) * | 2012-10-19 | 2014-04-24 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Pharmaceutical compositions of dabigatran free base |
WO2014060561A1 (en) * | 2012-10-19 | 2014-04-24 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Oral pharmaceutical formulations comprising dabigatran |
CN103788063B (zh) * | 2012-10-29 | 2016-01-20 | 天津药物研究院 | 四水合达比加群酯晶体及其制备方法和药物用途 |
IN2013CH05441A (es) * | 2013-11-26 | 2015-05-29 | Aurobindo Pharma Ltd | |
CN104291789B (zh) * | 2014-09-28 | 2016-03-02 | 定远县绿苑新型建材有限公司 | 一种吸水性强的多孔砖及其制备方法 |
CN105560236B (zh) * | 2014-10-30 | 2019-03-15 | 成都百裕制药股份有限公司 | 一种含有银杏内酯b和非肽类凝血酶抑制剂的药物组合物及其制备方法和用途 |
CN108133754B (zh) * | 2017-12-19 | 2019-03-12 | 中国医学科学院阜外医院 | 一种溶栓后出血风险的预测系统 |
CN110339193B (zh) | 2018-04-04 | 2022-04-29 | 上海汉都医药科技有限公司 | 含达比加群酯的药物组合物及其制备方法 |
US11696902B2 (en) | 2018-08-14 | 2023-07-11 | AltaThera Pharmaceuticals, LLC | Method of initiating and escalating sotalol hydrochloride dosing |
US11610660B1 (en) | 2021-08-20 | 2023-03-21 | AltaThera Pharmaceuticals LLC | Antiarrhythmic drug dosing methods, medical devices, and systems |
CN111983085B (zh) * | 2020-08-21 | 2022-05-31 | 江苏省食品药品监督检验研究院 | 一组血清代谢标志物在预测华法林个体药效和指导华法林个体化用药中的应用 |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6087380A (en) | 1949-11-24 | 2000-07-11 | Boehringer Ingelheim Pharma Kg | Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions |
US4145308A (en) | 1977-07-07 | 1979-03-20 | General Electric Company | Anti-foam silicone emulsion, and preparation and use thereof |
US4191741A (en) | 1978-09-22 | 1980-03-04 | Eli Lilly And Company | Removable drug implant |
US5422121A (en) | 1990-11-14 | 1995-06-06 | Rohm Gmbh | Oral dosage unit form |
US5277820A (en) | 1992-02-06 | 1994-01-11 | Hemocleanse, Inc. | Device and method for extracorporeal blood treatment |
EP1078917A4 (en) | 1998-02-17 | 2002-11-06 | Ono Pharmaceutical Co | AMIDINO DERIVATIVES FOR USE AS ACTIVE INGREDIENTS AND MEDICINES CONTAINING THEM |
GB0003782D0 (en) | 2000-02-17 | 2000-04-05 | Dumex Ltd As | Process |
US6620439B1 (en) | 2000-10-03 | 2003-09-16 | Atul M. Mehta | Chrono delivery formulations and method of use thereof |
US6555581B1 (en) * | 2001-02-15 | 2003-04-29 | Jones Pharma, Inc. | Levothyroxine compositions and methods |
US20030181488A1 (en) | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof |
DE10339862A1 (de) | 2003-08-29 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel |
EP1807086A1 (en) | 2004-10-25 | 2007-07-18 | Boehringer Ingelheim International GmbH | Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases |
US20060222640A1 (en) * | 2005-03-29 | 2006-10-05 | Boehringer Ingelheim International Gmbh | New pharmaceutical compositions for treatment of thrombosis |
DE102005020002A1 (de) | 2005-04-27 | 2006-11-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Physiologisch verträgliche Salze von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester |
DE102005025728A1 (de) | 2005-06-04 | 2006-12-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Polymorphe von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-Propionsäure-ethylester |
US20070079972A1 (en) | 2005-09-23 | 2007-04-12 | Fireaway Llc | Manually activated, portable fire-extinguishing aerosol generator |
DE102005061623A1 (de) | 2005-12-21 | 2007-06-28 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verbessertes Verfahren zur Herstellung von 4-(Benzimidazolylmethylamino)-Benzamidinen und deren Salzen |
DE102005061624A1 (de) | 2005-12-21 | 2007-06-28 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verbessertes Verfahren zur Herstellung von Salzen von 4-(Benzimidazolylmethylamino)-Benzamidinen |
CA2657270A1 (en) | 2006-07-17 | 2008-01-24 | Boehringer Ingelheim International Gmbh | New paediatric indications for direct thrombin inhibitors |
CA2657269A1 (en) | 2006-07-17 | 2008-01-24 | Boehringer Ingelheim International Gmbh | New indications for direct thrombin inhibitors |
JP2009543842A (ja) * | 2006-07-17 | 2009-12-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 心臓血管分野における直接トロンビン阻害薬のための新規適応 |
US20100087488A1 (en) | 2006-10-10 | 2010-04-08 | Boehringer Ingelheim International Gmgh | Physiologically Acceptable Salts of 3-[(2--1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester |
DE102006054005A1 (de) | 2006-11-16 | 2008-05-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Polymorphe von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester |
EP1956018A1 (de) | 2007-02-06 | 2008-08-13 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verfahren zur Herstellung eines Benzimidazolderivats |
RU2010143901A (ru) | 2008-03-28 | 2012-05-10 | Бёрингер Ингельхайм Интернациональ Гмбх (De) | Способ получения композиций дабигатрана для перорального введения |
WO2009118321A1 (de) | 2008-03-28 | 2009-10-01 | Boehringer Ingelheim International Gmbh | Verfahren zur herstellung von säurepellets |
AU2009259440B2 (en) | 2008-06-16 | 2014-05-29 | Boehringer Ingelheim International Gmbh | Method for producing an intermediate product of dabigatran etexilate |
EP2300431B1 (en) | 2008-06-16 | 2016-01-06 | Boehringer Ingelheim International GmbH | Process for the manufacture of an intermediate in the synthesis of dabigatran |
NZ589746A (en) | 2008-07-14 | 2012-10-26 | Boehringer Ingelheim Int | Method for manufacturing medicinal compounds containing dabigatran |
BRPI0917507A2 (pt) | 2008-08-19 | 2015-11-17 | Boehring Ingelheim Internat Gmbh | dabigatrana para a caterização cardíaca percutânea intervencionista |
EP2328581A1 (en) | 2008-08-19 | 2011-06-08 | Boehringer Ingelheim International GmbH | Use of dabigatranetexilate for treating patients with pulmonary hypertension |
CA2734809A1 (en) | 2008-08-19 | 2010-02-25 | Boehringer Ingelheim International Gmbh | Dabigatran in tumour therapy |
KR20110082563A (ko) | 2008-11-11 | 2011-07-19 | 베링거 인겔하임 인터내셔날 게엠베하 | 통상의 와파린 요법에 비해 효능이 향상된 다비가트란 에텍실레이트 또는 이의 염을 사용하여 혈전증을 치료하거나 예방하는 방법 |
JP2013510072A (ja) | 2008-11-11 | 2013-03-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 従来のワルファリン治療に対して安全性プロフィールが改善されたダビガトランエテキシレートまたはその塩を使用して血栓症を治療または予防するための方法 |
NZ592615A (en) | 2008-11-11 | 2013-06-28 | Boehringer Ingelheim Int | Method for treating or preventing thrombosis using 150 mg b.i.d. of dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy |
AU2010209804B2 (en) | 2009-02-02 | 2015-07-16 | Boehringer Ingelheim International Gmbh | Lyophilised dabigatran |
US8399678B2 (en) | 2009-11-18 | 2013-03-19 | Boehringer Ingelheim International Gmbh | Process for the manufacture of dabigatran etexilate |
-
2009
- 2009-11-10 JP JP2011535124A patent/JP2013510072A/ja active Pending
- 2009-11-10 MX MX2011004614A patent/MX2011004614A/es not_active Application Discontinuation
- 2009-11-10 CN CN2013101863297A patent/CN103356614A/zh active Pending
- 2009-11-10 EA EA201100756A patent/EA201100756A1/ru unknown
- 2009-11-10 CA CA2738883A patent/CA2738883A1/en not_active Abandoned
- 2009-11-10 BR BRPI0921479A patent/BRPI0921479A2/pt not_active IP Right Cessation
- 2009-11-10 PE PE2011001005A patent/PE20110431A1/es not_active Application Discontinuation
- 2009-11-10 EP EP09756704A patent/EP2358368A1/en not_active Withdrawn
- 2009-11-10 NZ NZ592616A patent/NZ592616A/xx not_active IP Right Cessation
- 2009-11-10 AR ARP090104346A patent/AR074313A1/es unknown
- 2009-11-10 WO PCT/EP2009/064873 patent/WO2010055021A1/en active Application Filing
- 2009-11-10 AU AU2009315729A patent/AU2009315729A1/en not_active Abandoned
- 2009-11-10 CN CN2009801442124A patent/CN102209544A/zh active Pending
- 2009-11-10 TW TW098138131A patent/TW201022237A/zh unknown
- 2009-11-10 US US13/128,459 patent/US8962574B2/en active Active
- 2009-11-10 KR KR1020117010630A patent/KR20110086700A/ko not_active Application Discontinuation
-
2010
- 2010-06-17 US US12/817,347 patent/US20100322869A1/en not_active Abandoned
-
2011
- 2011-03-22 IL IL211852A patent/IL211852A0/en unknown
- 2011-04-11 CL CL2011000798A patent/CL2011000798A1/es unknown
- 2011-05-04 EC EC2011011030A patent/ECSP11011030A/es unknown
- 2011-05-10 TN TN2011000228A patent/TN2011000228A1/fr unknown
- 2011-05-11 MA MA33834A patent/MA32786B1/fr unknown
- 2011-05-11 CO CO11058047A patent/CO6361938A2/es not_active Application Discontinuation
-
2012
- 2012-07-13 US US13/548,423 patent/US20120282187A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
NZ592616A (en) | 2013-04-26 |
BRPI0921479A2 (pt) | 2016-01-12 |
PE20110431A1 (es) | 2011-07-13 |
TW201022237A (en) | 2010-06-16 |
US8962574B2 (en) | 2015-02-24 |
US20110269703A1 (en) | 2011-11-03 |
WO2010055021A1 (en) | 2010-05-20 |
AU2009315729A1 (en) | 2010-05-20 |
US20100322869A1 (en) | 2010-12-23 |
MA32786B1 (fr) | 2011-11-01 |
CL2011000798A1 (es) | 2012-01-27 |
ECSP11011030A (es) | 2011-07-29 |
JP2013510072A (ja) | 2013-03-21 |
EP2358368A1 (en) | 2011-08-24 |
MX2011004614A (es) | 2011-05-31 |
CN103356614A (zh) | 2013-10-23 |
CA2738883A1 (en) | 2010-05-20 |
KR20110086700A (ko) | 2011-07-29 |
US20120282187A1 (en) | 2012-11-08 |
EA201100756A1 (ru) | 2011-12-30 |
CN102209544A (zh) | 2011-10-05 |
AR074313A1 (es) | 2011-01-05 |
IL211852A0 (en) | 2011-06-30 |
TN2011000228A1 (en) | 2012-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6361938A2 (es) | Metodo para tratar o prevenir la trombosis usando etexilato de dabigatran o una sal del mismo con un perfil de seguridad mejorado sobre la terapia con warfarina convencional | |
CO6382133A2 (es) | Metodo para tratar o prevenir la trombosis usando etexilato de dabigatran o una sal del mismo con una eficacia mejorada sobre la terapia con warfarina convencional | |
CR11510A (es) | Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer | |
NO20065847L (no) | Difenylimidazopyrimidiner og -imidazolaminer som inhibitorer av B-sekretase | |
AR067495A1 (es) | Composiciones farmaceuticas y procedimientode tratamientos de trastornos de ojo seco | |
AR085173A1 (es) | Terapia de combinacion para el tratamiento de enfermedades oncologicas y fibroticas | |
WO2009039460A3 (en) | Co-administration of pimavanserin with other agents | |
BR112015020466A2 (pt) | inibidores de cdc7 | |
UY35962A (es) | Formulaciones de liberación modificada de pridopidina | |
AR065033A1 (es) | Metodos para prevenir y tratar trastornos neurodegenerativos | |
AR119158A1 (es) | Tratamientos de angioedema hereditario | |
AR075423A1 (es) | Composicion farmaceutica que comprende un inhibidor de sglt-2, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y sus usos | |
DOP2009000243A (es) | Inhibidores de piridopirimidinona de pi3k-alfa en el tratamiento del cancer | |
EA201490254A1 (ru) | Комбинированное лечение гепатита с | |
SG156681A1 (en) | Use of ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure | |
CL2009000803A1 (es) | Uso de una variante de igf-1 pegilada para tratar, prevenir un trastorno neuromuscular; metodo para el tratamiento, prevencion y/o demora de un trastorno neuromuscular; composicion que comprende la variante de igf-1 modificada | |
AR093182A1 (es) | Metodo para tratar el sobrepeso o la obesidad | |
CO6270217A2 (es) | Formulaciones galenicas de alisquireno y valsartan | |
PE20230091A1 (es) | Conjugados terapeuticos | |
CO6430497A2 (es) | Metodo o sistema que usa biomarcadores para el seguimiento de un tratamiento | |
CL2011000805A1 (es) | Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion de lictus en pacientes que padecen fibrilacion auricular. | |
AR072954A1 (es) | Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administracion de dronedarona, producto de fabricacion y envase | |
AR088497A1 (es) | Composiciones farmaceuticas de combinaciones de inhibidores de la dipeptidil peptidasa 4 con atorvastatina | |
AR081574A1 (es) | Derivados de acido 1-(2-fluorobifenil-4-il)ciclopropanocarboxilico para la terapia de enfermedades prionicas | |
UA105645C2 (uk) | Застосування етексилату дабігатрану, необов'язково у формі фармацевтично прийнятної солі, для запобігання інсульту у пацієнта, що страждає від миготливої аритмії |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Application withdrawn |